282 related articles for article (PubMed ID: 26036639)
1. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S
Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639
[TBL] [Abstract][Full Text] [Related]
2. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
[No Abstract] [Full Text] [Related]
3. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
[TBL] [Abstract][Full Text] [Related]
4. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
[TBL] [Abstract][Full Text] [Related]
5. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
Åman P; Dolatabadi S; Svec D; Jonasson E; Safavi S; Andersson D; Grundevik P; Thomsen C; Ståhlberg A
J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
[TBL] [Abstract][Full Text] [Related]
6. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
7. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
[TBL] [Abstract][Full Text] [Related]
9. Requirement for YAP1 signaling in myxoid liposarcoma.
Trautmann M; Cheng YY; Jensen P; Azoitei N; Brunner I; Hüllein J; Slabicki M; Isfort I; Cyra M; Berthold R; Wardelmann E; Huss S; Altvater B; Rossig C; Hafner S; Simmet T; Ståhlberg A; Åman P; Zenz T; Lange U; Kindler T; Scholl C; Hartmann W; Fröhling S
EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 30898787
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.
St Bernard R; Zheng L; Liu W; Winer D; Asa SL; Ezzat S
Endocrinology; 2005 Mar; 146(3):1145-53. PubMed ID: 15564323
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis.
Ye T; Wei X; Yin T; Xia Y; Li D; Shao B; Song X; He S; Luo M; Gao X; He Z; Luo C; Xiong Y; Wang N; Zeng J; Zhao L; Shen G; Xie Y; Yu L; Wei Y
Breast Cancer Res Treat; 2014 Feb; 143(3):435-46. PubMed ID: 24398778
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma.
Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Byron SA; Loch DC; Pollock PM
Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
[TBL] [Abstract][Full Text] [Related]
14. Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.
Willems SM; Schrage YM; Bruijn IH; Szuhai K; Hogendoorn PC; Bovée JV
Mol Cancer; 2010 Sep; 9():257. PubMed ID: 20863376
[TBL] [Abstract][Full Text] [Related]
15. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.
Mori M; Mori T; Yamamoto A; Takagi S; Ueda M
Hum Cell; 2019 Jul; 32(3):367-378. PubMed ID: 30963412
[TBL] [Abstract][Full Text] [Related]
16. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
Narendra S; Valente A; Tull J; Zhang S
Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
[TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.
Safavi S; Järnum S; Vannas C; Udhane S; Jonasson E; Tomic TT; Grundevik P; Fagman H; Hansson M; Kalender Z; Jauhiainen A; Dolatabadi S; Stratford EW; Myklebost O; Eriksson M; Stenman G; Schneider-Stock R; Ståhlberg A; Åman P
Oncotarget; 2016 Jan; 7(1):433-45. PubMed ID: 26595521
[TBL] [Abstract][Full Text] [Related]
18. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.
Dey JH; Bianchi F; Voshol J; Bonenfant D; Oakeley EJ; Hynes NE
Cancer Res; 2010 May; 70(10):4151-62. PubMed ID: 20460524
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.
Ranji P; Jonasson E; Andersson L; Filges S; Luna Santamaría M; Vannas C; Dolatabadi S; Gustafsson A; Myklebost O; Håkansson J; Fagman H; Landberg G; Åman P; Ståhlberg A
J Transl Med; 2024 Apr; 22(1):389. PubMed ID: 38671504
[TBL] [Abstract][Full Text] [Related]
20. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
